Shots: The approval is based on KEYNOTE-057 (NCT02625961) study involves assessing of Keytruda (200 mg, q3w) in 96 patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in […]readmore
Tags : Non-Muscle Invasive Bladder Cancer
Shots: The application is based on P-II KEYNOTE-057 trial which involves assessing of Keytruda (200mg, q3w) in 102 patients with BCG unresponsive, high-risk NMIBC with carcinoma in-situ (CIS) with/out papillary […]readmore